HIV Latency Reversal Agents: Effective for Cure?

HIV: Current Research
doi 10.4172/2572-0805.1000e107
Full Text
Abstract

Available in full text

Date
Authors
Publisher

OMICS Publishing Group

Related search

HIV-1 Reservoirs and Latency: Critical Barriers and Clues for HIV / AIDS Cure

2012English

The Inhibitor Apoptosis Protein Antagonist Debio 1143 Is an Attractive HIV-1 Latency Reversal Candidate

PLoS ONE
Multidisciplinary
2019English

Electro-Turmeric (Curcumin)-Therapy for Effective Cancer Cure

Journal of Nanomedicine & Biotherapeutic Discovery
2012English

The Effect of Latency Reversal Agents on Primary CD8 + T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication

EBioMedicine
BiochemistryMedicineGeneticsMolecular Biology
2016English

High Throughput in Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing

Journal of Visualized Experiments
ImmunologyMolecular BiologyBiochemistryMicrobiology Chemical EngineeringNeuroscienceGenetics
2019English

Quantification of HIV-1 Latency Reversal in Resting CD4+ T Cells From Patients on Suppressive Antiretroviral Therapy

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2014English

A Cure for HIV: How Would We Know?

The Lancet HIV
EpidemiologyInfectious DiseasesImmunologyVirology
2020English

Nonnucleoside Reverse Transcriptase Inhibitors Reduce HIV-1 Production From Latently Infected Resting CD4 + T Cells Following Latency Reversal

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2016English

Reversal Agents for Use With Direct and Indirect Anticoagulants

American Journal of Health-System Pharmacy
MedicineHealth PolicyPharmacologyPharmacy
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy